Agreement with Eli Lilly and Company (Related Party) (Tables)

3 Months Ended

Mar. 31, 2019

Agreement with Eli Lilly and Company (Related Party)

Summary of deferred revenue included in the Company’s balance sheets

As of March 31, 2019, deferred revenue included in the Company’s balance sheets comprised the following (in thousands):

	March 31,		December 31,
	2019		2018
Deferred revenue from related party, beginning of period	$	26,725	$	—
Up-front payment		—		25,000
Attributed premium on the proceeds from Lilly’s investment in the Company		—		1,725
Research and development support billing		500		—
Revenue from related party recognized		(1,357)		—
Total deferred revenue from related party, end of period		25,868		26,725
Less: Deferred revenue from related party, current portion		(5,240)		(4,989)
Deferred revenue from related party, non-current portion	$	20,628	$	21,736